Esperion Therapeutics stock (US2964331002): buyout by Archimed and fresh earnings put focus on futur
Esperion Therapeutics is being acquired by healthcare investor Archimed in a deal valued at up to $1.1 billion following the biotech's latest quarterly earnings report. This acquisition puts the Nasdaq-listed cholesterol specialist back on investors' radar, combining an M&A story with financial results. The deal highlights the strategic rationale for Archimed to accelerate growth through operational support and capital, potentially increasing flexibility for Esperion without public market pressures.
ETFs Investing in Esperion Therapeutics, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Esperion Therapeutics, Inc. (0ET). The list, sorted by market value, includes details such as issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, and 3-year total return for each ETF. The ETFs primarily include small-cap, health care, and biotech funds from major issuers like BlackRock, State Street, and Vanguard.
Esperion Therapeutics (ESPR) price target decreased by 59.91% to 2.97
This article reports that the price target for Esperion Therapeutics (ESPR) has been significantly decreased by 59.91% to $2.97. No further details regarding the reason for this reduction or the analyst who made the change are available in the provided content.
Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization
Esperion Therapeutics has estimated the annual economic burden of heart failure in the U.S. to be $46 billion, encompassing healthcare, medications, and lost productivity. The company advocates for optimizing guideline-directed therapy and enhancing patient education to achieve significant cost savings and improved health outcomes. These strategies are presented as both financially beneficial and life-saving for the healthcare system and society.
Drugmaker Esperion gives new hires 260,000 stock units to join
Esperion (NASDAQ: ESPR) has granted 260,000 restricted stock units (RSUs) to 23 new employees under its 2017 Inducement Equity Incentive Plan, adhering to NASDAQ Rule 5635(c)(4). These RSUs will vest 25% after one year and the remaining 75% in twelve quarterly installments, contingent on continued employment. This move aims to attract and retain talent, aligning employee incentives with shareholder interests, though it may incrementally dilute existing shareholders upon vesting.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion announced it granted 260,000 restricted stock units (RSUs) to 23 new employees on May 12, 2026, under its 2017 Inducement Equity Incentive Plan. These grants are designed to attract new talent as an inducement to employment, aligning with NASDAQ Listing Rules. The RSUs will vest over time, with a portion vesting on the one-year anniversary of the start date and the remainder in quarterly installments, subject to continued employment.
Esperion Therapeutics stock (US2964331002): Archimed acquisition deal closes chapter on independent
Esperion Therapeutics has agreed to be acquired by Archimed for up to $1.1 billion, with shareholders receiving $3.16 per share upfront and potential milestone payments. This transaction, expected to close in Q3 2026, represents a significant premium for Esperion shareholders and will make the company privately held. The deal highlights continued investor interest in cardiovascular therapeutics.
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Esperion Therapeutics (ESPR) stock has surged nearly 44% in the past month following an announcement that it will be acquired by Archimed for up to $1.1 billion, including potential milestone payments. The transaction offers Esperion shareholders $3.16 per share in cash at closing, plus contingent payments tied to future sales of its key products, Nexletol, Nexlizet, and Enbumyst. The deal is expected to close in the third quarter of 2026, after which Esperion will become a private company.
New cholesterol data in kids and statin-intolerant adults at EAS 2026
Esperion (NASDAQ: ESPR) announced that it will present new analyses and encore presentations on bempedoic acid at the European Atherosclerosis Society (EAS) Congress 2026. This data includes findings from a Phase 2 pediatric study showing LDL-C reductions in children with heterozygous familial hypercholesterolemia (HeFH), supporting advancement to Phase 3 development. Additionally, new analyses from the CLEAR Outcomes trial will identify factors associated with enhanced LDL-C reductions in statin-intolerant adults.
Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk
Esperion Therapeutics' latest 10-Q filing contains forward-looking statements that inherently carry significant uncertainty, according to an external analysis. These statements, which cover accounting, financial, and operational projections, are not guarantees, meaning actual results could substantially differ and expose investors to heightened risks. The disclaimer from Esperion Therapeutics suggests considerable variability in its future performance due to internal plans and external economic factors, which could affect company valuation, risk premiums, and stakeholder confidence.
Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives
Esperion Therapeutics (ESPR) reported a significant Q4 2025 profit of US$61.8 million, moving from a loss in the previous quarter, and revenue of US$168.4 million. While bulls highlight this step towards profitability and projected revenue growth, bears point to ongoing trailing losses, negative shareholders' equity, recent shareholder dilution, and insider selling as concerns. The article discusses how these factors influence investor perception and the company's valuation.
Esperion Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Esperion Therapeutics Inc. has released its earnings summary for the quarter that ended on March 31. The report, provided by Refinitiv, gives a brief overview of the company's financial performance. Further details would typically be available upon logging into a TradingView account.
Buyout values Esperion (NASDAQ: ESPR) at $3.16 in cash plus CVR
Esperion Therapeutics reported strong Q1 2026 results with revenue up to $80.1 million and a narrower net loss, driven by product sales and collaboration revenue. The company is set to be acquired by Essence Parent Inc. for $3.16 per share in cash plus one contingent value right (CVR) tied to up to $100 million in future milestone payments, pending stockholder approval. Additionally, Esperion expanded its cardiovascular portfolio with the acquisition of Corstasis and its FDA-approved drug Enbumyst.
Esperion Therapeutics(ESPR) Stock Options Chain | Quotes & News
This article provides stock options chain data, quotes, and news for Esperion Therapeutics (ESPR). It serves as a resource for investors interested in the financial performance and options trading related to the company's stock.
United States - Goodwin Advises Esperion On $1.1 Billion Acquisition By ARCHIMED
Goodwin Procter LLP has advised Esperion Therapeutics on its acquisition by ARCHIMED, a healthcare-focused investment firm. The deal is valued at up to approximately $1.1 billion in total equity, with Esperion shareholders receiving an upfront cash payment of $3.16 per share and potential contingent milestone payments. Esperion, a biopharmaceutical company specializing in cardiometabolic and rare/orphan diseases, focuses on developing and commercializing therapies, including non-statin treatments for LDL-C levels, and is expanding its pipeline.
Esperion Therapeutics (Nasdaq:ESPR) - Stock Analysis
Esperion Therapeutics (ESPR) is a biopharmaceutical company focused on treatments for elevated LDL cholesterol. The company's stock is currently trading below its estimated fair value, with analysts forecasting significant earnings growth. Recent developments include an agreement to be acquired by ArchiMed SAS for approximately $830 million (up to $1.1 billion including milestones) and positive updates on its Vision 2040 plan and product labels.
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to ARCHIMED funds. Shareholders are set to receive $3.16 per share in cash plus contingent milestone payments. KSF is scrutinizing whether this consideration is adequate and if the process leading to the sale undervalues the company.
Esperion Therapeutics (NasdaqGM:ESPR) Stock Forecast & Analyst Predictions
This article provides a comprehensive overview of Esperion Therapeutics (ESPR) stock forecast and recent analyst predictions. It details the company's financial outlook, including projected earnings and revenue growth, and highlights significant corporate announcements such as FDA approvals for its drugs NEXLETOL and NEXLIZET, strategic acquisitions like Corstasis Therapeutics, and a definitive agreement for acquisition by unknown funds managed by ArchiMed SAS for approximately $830 million. The report also covers various narrative updates from analysts regarding price targets, potential risks, and the company's Vision 2040 plan for future growth and pipeline expansion.
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Shareholders are set to receive $3.16 per share in cash plus potential contingent milestone payments. KSF aims to determine if this offer undervalues the company and encourages shareholders to contact them regarding their legal rights.
Jefferies Downgrades Esperion Therapeutics to Hold From Buy, Adjusts Price Target to $3.28 From $5
Jefferies has downgraded Esperion Therapeutics (ESPR) from Buy to Hold and reduced its price target from $5 to $3.28. This follows similar downgrades from Needham and Piper Sandler, indicating a challenging outlook for the biopharmaceutical company. Esperion Therapeutics is focused on developing and commercializing oral non-statin medicines for patients at risk for cardiovascular disease with elevated LDL-C.
ESPR Jumps As Esperion Agrees To $1.1B Archimed Buyout
Esperion Therapeutics Inc. (ESPR) stock jumped 55.0% following news of a $1.1 billion buyout agreement with ARCHIMED. The deal, priced at $3.16 per share in cash plus a non-tradeable CVR, has shifted ESPR from a volatile biotech stock to an event-driven trade. Analysts note that while the acquisition de-risks liquidity and expands Esperion's cardiovascular platform, most of the upside is already priced in, with the stock now trading near the deal's cash component.
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Esperion Therapeutics, Inc. (NASDAQ: ESPR) to funds managed by ARCHIMED for $3.16 per share in cash plus contingent milestone payments. The firm is examining whether Esperion's board violated federal securities laws or breached fiduciary duties by failing to secure the best price, conduct a fair sales process, or disclose all material information to shareholders. Halper Sadeh LLC encourages Esperion shareholders to contact them to discuss their rights and options.
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Esperion Therapeutics, Inc. (NASDAQ: ESPR) regarding its recently announced transaction with ARCHIMED, specifically whether public shareholders are receiving a fair price. The investigation focuses on potential breaches of fiduciary duty, given the $3.16 cash per share plus contingent value rights totaling up to $1.1 billion, and concerns over limits on competing bids and substantial benefits for insiders. Shareholders are invited to contact Ademi LLP for more information about joining the investigation.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages
Esperion Therapeutics (NASDAQ:ESPR) has received an average "Moderate Buy" recommendation from seven research firms, with an average one-year price target of $5.54. This comes amidst an acquisition offer from ARCHIMED valuing the company at $1.1 billion, with shareholders receiving $3.16 per share plus potential milestone payments. However, several shareholder-rights law firms have launched investigations into whether the proposed acquisition price is fair, which could lead to litigation or price revisions.
Esperion to be Acquired by ARCHIMED
Esperion Therapeutics has entered into a definitive agreement to be acquired by ARCHIMED for up to approximately $1.1 billion in total equity value. Esperion shareholders will receive $3.16 per share in cash at closing, plus the right to participate in contingent milestone payments of up to $100 million tied to future net sales performance of its products. The transaction is expected to close in the third quarter of 2026, after which Esperion will become a privately held company.
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Esperion Therapeutics, Inc. (NASDAQ: ESPR) regarding its recently announced transaction with ARCHIMED. The firm is examining whether Esperion's board of directors is upholding its fiduciary duties to shareholders, particularly concerning the proposed $3.16 per share cash payment and contingent value rights, which could total up to $1.1 billion. The investigation also focuses on potential limitations imposed on competing bids, which could disadvantage public shareholders.
Ademi LLP Investigates Whether Esperion Therapeutics, Inc. Is Obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Esperion (NASDAQ: ESPR) for potential breaches of fiduciary duty due to its transaction with ARCHIMED. The investigation focuses on whether the $3.16 per share cash payment, plus contingent value rights, and change of control arrangements for insiders, provide a fair price for public shareholders. Concerns include a significant penalty clause that may restrict competing bids for Esperion.
ARCHIMED to buy Esperion (Nasdaq: ESPR) for $3.16 per share plus CVRs
Esperion Therapeutics will be acquired by Essence Parent Inc., an affiliate of ARCHIMED, for $3.16 in cash per share plus one contingent value right (CVR) per share, potentially totaling an additional $100 million if milestones are met. The deal, valued at up to $1.1 billion including CVRs, offers a 58% premium to Esperion's April 30, 2026 closing price. The transaction is expected to close in the third quarter of 2026, pending shareholder and regulatory approvals.
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
Esperion Therapeutics is set to be acquired and taken private by healthcare investment firm ArchiMed in a deal potentially worth up to $1.1 billion. ArchiMed will pay $3.16 per share upfront, representing a 58% premium, plus contingent milestone payments tied to future sales of Esperion’s drugs Nexletol, Nexlizet, and the newly acquired Enbumyst. The acquisition is expected to close in the third quarter, after which Esperion will delist from Nasdaq.
ESPR Rallies As Royalty Deal Fuels Corstasis Expansion
Esperion Therapeutics Inc. (ESPR) stock rallied 55.75% following a $50 million royalty financing deal with Athyrium Capital, which monetizes Japan bempedoic acid royalties to fund growth. The company also completed its acquisition of Corstasis Therapeutics, adding the FDA-approved nasal spray diuretic Enbumyst to its cardiovascular portfolio. These strategic moves aim to diversify revenue and leverage Esperion's existing sales infrastructure, with traders watching upcoming Q1 2026 results for further insights.
Rumor Desk: ESPERION PARTNERSHIP WITH BIG PHARMA IN THE WORKS. Stock Price Will Double
Speculation is mounting that Esperion Therapeutics ($ESPR) could be on the verge of a significant partnership with a major pharmaceutical company like AstraZeneca ($AZN), given recent conference overlap and AstraZeneca's need for oral lipid-lowering therapies. Despite strong analyst ratings and accelerating fundamentals, Esperion's stock trades well below consensus price targets, with a substantial short interest that could trigger a rapid price increase if a partnership is announced. The company's core assets, NEXLETOL and NEXLIZET, offer differentiated oral therapies, and a partnership would provide global commercial acceleration and validate Esperion's long-term strategy for profitability by 2026.
Esperion to Report First Quarter 2026 Financial Results on May 7
Esperion Therapeutics, Inc. announced it will release its first quarter 2026 financial results before market open on Thursday, May 7, 2026. Management will host a webcast at 8:00 a.m. ET on the same day to discuss the results and provide business updates. The company is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, currently marketing two oral, non-statin therapies for LDL-C management.
Esperion sets May 7 earnings release, 8 a.m. ET webcast
Esperion (NASDAQ: ESPR) announced it will report Q1 2026 financial results before market open on May 7, 2026. Management will host a live webcast at 8:00 a.m. ET on the same day to discuss the results and provide business updates, with a replay available for approximately 90 days. Historically, similar announcements have led to modest stock movements, with the actual financial data and forward commentary expected to be the key catalysts.
Esperion to Report First Quarter 2026 Financial Results on May 7
Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced it will report its first-quarter 2026 financial results before market open on Thursday, May 7, 2026. Following the release, the company will host a webcast at 8:00 a.m. ET to discuss these results and provide business updates. Esperion is a commercial-stage biopharmaceutical company focused on cardiovascular and rare disease therapies.
Esperion to Report First Quarter 2026 Financial Results on May 7
Esperion announced it will release its first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates. The company is a commercial-stage biopharmaceutical firm focusing on cardiometabolic and rare/orphan disease therapies, with two marketed oral non-statin therapies for LDL-C.
First quarter 2026 results set for May 7 as Esperion Therapeutics outlines earnings calendar
Esperion Therapeutics has announced that it will release its first-quarter 2026 financial results on May 7. This report is highly anticipated by investors and analysts who will be looking for key updates on the company's revenue, operating expenses, and therapy pipeline progress. The company recently achieved recognition as the 88th fastest-growing company in the Americas and presented new data for its drug NEXLETOL, adding to the focus on its upcoming financial disclosures.
Esperion to Report First Quarter 2026 Financial Results on May 7
Esperion announced it will release its first-quarter 2026 financial results on Thursday, May 7, 2026, before the market opens. Management will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates. The company is a commercial-stage biopharmaceutical firm focused on cardiometabolic and rare/orphan disease therapies.
Wasatch Advisors takes 6.1% stake in Esperion Therapeutics (NASDAQ: ESPR)
Wasatch Advisors has reported a 6.1% ownership stake in Esperion Therapeutics (NASDAQ: ESPR) through a SCHEDULE 13G SEC filing. This translates to beneficial ownership of 15,768,897 shares, with sole voting power for 12,377,523 shares and sole dispositive power for all beneficially owned shares. The filing, signed by CEO Mike Yeates on April 22, 2026, indicates a passive investment intent, noting that the stake is significant but does not imply control.
Esperion Therapeutics spotlights 2026 ACC AHA multisociety guideline for dyslipidemia management
Esperion Therapeutics has drawn attention to the new 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia, with discussion from cardiovascular medicine figures Dr. Steve Nissen and Dr. C. Michael Gibson. These guidelines are anticipated to significantly impact future cholesterol and cardiovascular risk management. The company, recently ranked 88th on the Financial Times Americas Fastest Growing Companies 2026 list, has also highlighted key data from its NEXLETOL CLEAR Outcomes study, maintaining its prominence in the cardiovascular field.
[ARS] Esperion Therapeutics, Inc. SEC Filing
Esperion Therapeutics, Inc. (ESPR) filed an ARS form with the SEC on April 16, 2026, at 04:14 PM UTC. This filing has a low impact and neutral sentiment. The document is available as a PDF on the SEC EDGAR website.
Esperion Therapeutics Target of Unusually Large Options Trading (NASDAQ:ESPR)
Esperion Therapeutics (NASDAQ:ESPR) experienced unusually high options trading activity, with call options increasing by 98% and the stock rising 1.7% on Wednesday. The company maintains a "Moderate Buy" consensus rating and a $7.60 target price from analysts, while institutional investors have also significantly increased their holdings. This surge in trading and investment comes despite Esperion slightly missing its most recent EPS estimates.
Esperion Therapeutics (NASDAQ:ESPR) Trading Down 5.2% - Here's What Happened
Esperion Therapeutics (NASDAQ:ESPR) shares fell 5.2% on Tuesday, trading at $2.1050 on lower than average volume. Despite missing EPS expectations slightly, the company exceeded revenue forecasts and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $7.60. Institutional investors, including hedge funds, have been increasing their positions in the biopharmaceutical company.
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $5
Needham has reiterated its Buy rating for Esperion Therapeutics (ESPR.US) and maintained its price target of $5. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference
Esperion Therapeutics presented at Needham & Company’s 25th Annual Healthcare Conference, reporting 38% year-over-year revenue growth and highlighting a recent guideline update that provides multiple Class 1A recommendations for its bempedoic acid therapies. The company also detailed the acquisition of Corstasis and its nasally delivered loop diuretic, Enbumyst, with commercial launch planned for September 2026, and outlined pipeline updates including a triple-combination LDL therapy and a primary sclerosing cholangitis program.
Personalized treatments advance as Esperion Therapeutics urges broader use of hsCRP in heart care
Esperion Therapeutics is advocating for the broader integration of high-sensitivity C-reactive protein (hsCRP) in cardiovascular care. The company asserts that hsCRP is a crucial biomarker for identifying residual inflammatory risk in patients, even those who have achieved their LDL-C targets. This move aims to promote more personalized and biomarker-driven approaches to heart health management.
ESPR Forecast, Price Target & Analyst Ratings | ESPERION THERAPEUTICS INC (NASDAQ:ESPR)
This article provides an in-depth analyst forecast for ESPERION THERAPEUTICS INC (ESPR), noting a consensus price target of $6.86, suggesting a 215.99% upside. It details future earnings estimates, projecting Q1 2026 EPS at -$0.03 and revenue at $96.129M, alongside a ChartMill Buy Consensus Rating of 78.57%. The report also includes historical analyst ratings, recent upgrades/downgrades, and long-term growth forecasts for EPS, revenue, and EBIT.
Esperion Therapeutics Stock Dips After Q4 Earnings Miss Expectations
Esperion Therapeutics Inc. (ESPR) stock dipped by 11.57% after its Q4 EPS of $0.22 missed analyst estimates of $0.27. This disappointing earnings report, despite revenues exceeding $403 million, has raised concerns among investors about the company's financial performance, profitability margins, and competitive challenges. Market analysts are closely watching Esperion's strategic responses to address liquidity constraints and high research costs.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts
Esperion Therapeutics, Inc. (NASDAQ:ESPR) has received a "Moderate Buy" consensus rating from eight analysts, with an average one-year price target of $7.60. Despite missing EPS estimates slightly, the company exceeded revenue expectations. Institutional investors, including Vanguard and State Street, have increased their stakes, with institutions now owning approximately 47.39% of the company.
Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co.
JPMorgan Chase & Co. has significantly increased its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 68.4% in the third quarter of 2025, now owning 945,491 shares valued at approximately $2.51 million. This increase follows Esperion's acquisition of Corstasis and a $50 million Japan royalty financing deal, both aimed at boosting portfolio diversification and liquidity. While analysts have mixed views with some lowering near-term EPS estimates, the consensus still reflects a "Moderate Buy" rating with a target price of $7.60, anticipating profitability by 2027-2028.
ESPR Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Esperion Therapeutics Inc.'s (ESPR) financial performance, focusing on its profitability and margins. ESPR boasts a gross margin of 83.46%, an operating margin of 50.60%, and a net margin of 36.71%. The company is benchmarked against competitors MNKD and OMER, highlighting its strong gross margin compared to MNKD.
